Deguelin, a selective silencer of the NPM1 mutant, potentiates apoptosis and induces differentiation in AML cells carrying the NPM1 mutation

Annals of Hematology

Volumn 94, Issue 2, 2015, Pages 201-210

  Yi, Sha ^a   Wen, Lu ^a   He, Jing ^a   Wang, Youping ^a   Zhao, Fei ^a   Zhao, Jie ^a   Zhao, Zichu ^a   Cui, Guohui ^a   Chen, Yan ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Acute myeloid leukemia; Apoptosis; Deguelin; Differentiation; NPM1 mutation

Indexed keywords

BETULIC ACID; CASPASE 3; CASPASE 6; CASPASE 8; CCAAT ENHANCER BINDING PROTEIN ALPHA; DEGUELIN; NUCLEOPHOSMIN; ORIDONIN; PROTEIN P53; SMALL INTERFERING RNA; TRIPTOLIDE; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; MUTANT PROTEIN; NUCLEAR PROTEIN; ROTENONE;

ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL DIFFERENTIATION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVATION; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ACUTE DISEASE; ANALOGS AND DERIVATIVES; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; MYELOID LEUKEMIA; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

ACUTE DISEASE; APOPTOSIS; BLOTTING, WESTERN; CASPASE 6; CASPASE 8; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOID; MUTANT PROTEINS; MUTATION; NUCLEAR PROTEINS; RNA INTERFERENCE; ROTENONE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84926636926     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2206-x     Document Type: Article

References (33)

1. Okuwaki M (2008) The structure and functions of NPM1/Nucleophsmin/B23, a multifunctional nucleolar acidic protein. J Biochem 143(4):441–448, eng
2. Grisendi S, Mecucci C, Falini B, Pandolfi PP (2006) Nucleophosmin and cancer. Nat Rev Cancer 6(7):493–505, eng
3. Okuda M (2002) The role of nucleophosmin in centrosome duplication. Oncogene 21(40):6170–6174, eng
4. Murano K, Okuwaki M, Hisaoka M, Nagata K (2008) Transcription regulation of the rRNA gene by a multifunctional nucleolar protein, B23/nucleophosmin, through its histone chaperone activity. Mol Cell Biol 28(10):3114–3126, eng
5. Colombo E, Marine JC, Danovi D, Falini B, Pelicci PG (2002) Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol 4(7):529–533, Eng
6. Kuo ML, den Besten W, Bertwistle D, Roussel MF, Sherr CJ (2004) N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes Dev 18(15):1862–1874, eng
7. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352(3):254–266, eng
8. Falini B, Nicoletti I, Martelli MF, Mecucci C (2007) Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 109(3):874–885, eng
9. Cheng K, Sportoletti P, Ito K, Clohessy JG, Teruya-Feldstein J, Kutok JL et al (2010) The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model. Blood 115(16):3341–3345, eng
10. Bolli N, Payne EM, Grabher C, Lee JS, Johnston AB, Falini B et al (2010) Expression of the cytoplasmic NPM1 mutant (NPMc+) causes the expansion of hematopoietic cells in zebrafish. Blood 115(16):3329–3340, eng
11. Falini B, Martelli MP, Bolli N, Sportoletti P, Liso A, Tiacci E et al (2011) Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood 117(4):1109–1120, eng
12. Ji BC, Yu CC, Yang ST, Hsia TC, Yang JS, Lai KC et al (2012) Induction of DNA damage by deguelin is mediated through reducing DNA repair genes in human non-small cell lung cancer NCI-H460 cells. Oncol Rep 27(4):959–964, eng
13. Thamilselvan V, Menon M, Thamilselvan S (2011) Anticancer efficacy of deguelin in human prostate cancer cells targeting glycogen synthase kinase-3 beta/beta-catenin pathway. Int J Cancer 129(12):2916–2927, eng
14. Lee H, Lee JH, Jung KH, Hong SS (2010) Deguelin promotes apoptosis and inhibits angiogenesis of gastric cancer. Oncol Rep 24(4):957–963, eng
15. Murillo G, Peng X, Torres KE, Mehta RG (2009) Deguelin inhibits growth of breast cancer cells by modulating the expression of key members of the Wnt signaling pathway. Cancer Prev Res (Phila) 2(11):942–950, eng
16. Udeani GO, Gerhauser C, Thomas CF, Moon RC, Kosmeder JW, Kinghorn AD et al (1997) Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid. Cancer Res 57(16):3424–3428, eng
17. Murillo G, Kosmeder JW II, Pezzuto JM, Mehta RG (2003) Deguelin suppresses the formation of carcinogen-induced aberrant crypt foci in the colon of CF-1 mice. Int J Cancer 104(1):7–11, eng
18. Paulus P, Ockelmann P, Tacke S, Karnowski N, Ellinghaus P, Scheller B et al (2012) Deguelin attenuates reperfusion injury and improves outcome after orthotopic lung transplantation in the rat. PLoS One 7(6):e39265, eng
19. Liu HL, Chen Y, Cui GH, Wu QL, He J, Chen WH et al (2005) Deguelin regulates nuclear pore complex proteins Nup98 and Nup88 in U937 cells in vitro. Acta Pharmacol Sin 26(10):1265–1273, eng
20. Chen WH, Chen Y, Cui GH (2006) Deguelin inhibits expression of IkappaBalpha protein in Raji and U937 cells. Acta Pharmacol Sin 27(4):485–490, eng
21. Shu W, Chen Y, Wu Q, Li R, Cui G (2008) Deguelin represses both the expression of nucleophosmin and some nucleoporins: Nup88 and Nup214 in Jurkat cells. Biol Pharm Bull 31(1):27–32, eng
22. Balusu R, Fiskus W, Rao R, Chong DG, Nalluri S, Mudunuru U et al (2011) Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1. Blood 118(11):3096–3106, eng
23. Thornberry NA, Lazebnik Y (1998) Caspases: enemies within. Science 281(5381):1312–1316, eng
24. Bratton SB, MacFarlane M, Cain K, Cohen GM (2000) Protein complexes activate distinct caspase cascades in death receptor and stress-induced apoptosis. Exp Cell Res 256(1):27–33, eng
25. Greil R, Anether G, Johrer K, Tinhofer I (2003) Tuning the rheostat of the myelopoietic system via Fas and TRAIL. Crit Rev Immunol 23(4):301–322, eng
26. Leong SM, Tan BX, Bte Ahmad B, Yan T, Chee LY, Ang ST et al (2010) Mutant nucleophosmin deregulates cell death and myeloid differentiation through excessive caspase-6 and -8 inhibition. Blood 116(17):3286–3296, eng
27. Bortul R, Tazzari PL, Billi AM, Tabellini G, Mantovani I, Cappellini A et al (2005) Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway. Br J Haematol 129(5):677–686, eng
28. Carter BZ, Milella M, Tsao T, McQueen T, Schober WD, Hu W et al (2003) Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia 17(11):2081–2089, eng
29. Lew QJ, Tan CH, Gurumurthy M, Chu KL, Cheong N, Lane DP et al (2011) NPMc(+) AML cell line shows differential protein expression and lower sensitivity to DNA-damaging and p53-inducing anticancer compounds. Cell Cycle 10(12):1978–1987, eng
30. Falini B, Bolli N, Liso A, Martelli MP, Mannucci R, Pileri S et al (2009) Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia 23(10):1731–1743, eng
31. Rosenbauer F, Tenen DG (2007) Transcription factors in myeloid development: balancing differentiation with transformation. Nat Rev Immunol 7(2):105–117, eng
32. Pulikkan JA, Dengler V, Peer Zada AA, Kawasaki A, Geletu M, Pasalic Z et al (2010) Elevated PIN1 expression by C/EBPalpha-p30 blocks C/EBPalpha-induced granulocytic differentiation through c-Jun in AML. Leukemia 24(5):914–923, eng
33. Pandey P, Nakazawa A, Ito Y, Datta R, Kharbanda S, Kufe D (2000) Requirement for caspase activation in monocytic differentiation of myeloid leukemia cells. Oncogene 19(34):3941–3947, eng